Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Gastric Cancer
Clinical trial register · United States · industry-sponsored

Gastric Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 15 Oct 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2195
Lead sponsors
across recruiting studies
Top states
California 36 Florida 20 New York 20 Texas 19 Massachusetts 14
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca9 Merus B.V.2 TORL Biotherapeutics, LLC2 I-Mab Biopharma US Limited2 Sutro Biopharma, Inc.2
State
California36 Florida20 New York20 Texas19 Massachusetts14
All 42 states
Target enrolment
to

Gastric Cancer trials in the USA

48 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
NCT07807345Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
285
California, Florida, Massachusetts, Oklahoma, Texas, Virginia
2026-09-14
Recruiting
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
NCT07529808Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma
BigHat Biosciences, Inc.
Phase 1/2
164
California, Virginia
2026-07-16
Recruiting
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
NCT07432633Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma
Blue Earth Diagnostics
Phase 1/2
71
Texas
2026-02-19
Recruiting
I-Mab Biopharma US Limited
Phase 2
180
Arizona, California, Massachusetts
2026-02-11
Recruiting
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
Recruiting
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer
DrugPembrolizumab
Sutro Biopharma, Inc.
Phase 1
200
California, Colorado, District of Columbia, Florida, Massachusetts, New York, Texas, Virginia
2025-11-07
Recruiting
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916Metastatic Sarcoma, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
Lantheus Medical Imaging
Phase 1/2
26
California, Michigan, Ohio
2025-08
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
California, Colorado, Florida, Tennessee, Texas, Virginia, Washington
2025-07-25
Active, closed
Study for AZD4360 in Participants With Advanced Solid Tumours
NCT06921928Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
AstraZeneca
Phase 1/2
31
California, Rhode Island, Texas
2025-04-29
Recruiting
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Perspective Therapeutics
Phase 1/2
112
California, Florida, Kansas, Kentucky, Minnesota, Missouri, Nebraska, New York
2025-04-28
Recruiting
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer
Tanabe Pharma America, Inc.
Phase 1/2
27
California, Michigan, Ohio, Texas
2025-04-18
Recruiting
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
California, District of Columbia, Florida, South Carolina, Tennessee, Texas, Virginia
2025-01-29
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Arizona, Colorado, Florida, Illinois, Michigan, New York, Pennsylvania, Tennessee
2025-01-14
Recruiting
Shanghai Henlius Biotech
Phase 3
550
California, Colorado, Florida, Illinois, Iowa, Missouri, Nebraska, Nevada
2024-11-22
Recruiting
Chimeric Therapeutics
Phase 1/2
135
Georgia, Illinois, Pennsylvania, Tennessee
2024-05-15
Active, closed
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT06257264Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer
DrugsBGB-43395·Fulvestrant
BeiGene
Phase 1
103
California, Florida, Missouri, New Jersey, South Dakota, Texas
2024-03-11
Active, closed
AstraZeneca
Phase 3
594
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Idaho, Kentucky
2024-03-04
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
California, Connecticut, Florida, Illinois, Maryland, Minnesota, Missouri, New York
2024-02-26
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
California, Kentucky, New York, Rhode Island, Texas
2023-12-13
Recruiting
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsTRK-950·Ramucirumab·Paclitaxel
Toray Industries, Inc
Phase 2
146
California, Texas
2023-10-04
Recruiting
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.
Phase 1
165
California, Massachusetts, Tennessee, Texas
2023-09-14
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Florida, Minnesota, New York
2023-07-11
Active, closed
A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
NCT05789069Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer
DrugTislelizumab
HiFiBiO Therapeutics
Phase 1
83
California, Pennsylvania, Virginia
2023-05-09
Active, closed
Legend Biotech USA Inc
Phase 1
56
Florida, Michigan, New Jersey, New York, North Carolina, Oregon, Tennessee, Washington
2023-04-18
Recruiting
AstraZeneca
Phase 2
163
California, Louisiana, Michigan, New York, Pennsylvania
2023-01-16
Active, closed
Qurient Co., Ltd.
Phase 1/2
120
California, Kentucky
2023-01-12
Recruiting
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT05768932Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
SillaJen, Inc.
Phase 1
260
Connecticut, Florida, Georgia, Michigan, New York, Oregon, Texas
2022-12-14
Recruiting
AstraZeneca
Phase 2
454
California, Indiana, Kansas, Massachusetts, Michigan, New Jersey, New Mexico, New York
2022-09-06
Recruiting
Comprehensive Outcomes for After Cancer Health
NCT05349227Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
Pack Health
Not applicable
625
Florida, Massachusetts, Nebraska, New York, Ohio, Texas
2022-06-23
Active, closed
NGM Biopharmaceuticals, Inc
Phase 1
130
Arizona, California, Florida, Michigan, New York, Oklahoma, Texas
2022-03-31
Active, closed
HiFiBiO Therapeutics
Phase 1
72
Arizona, California, Florida, Minnesota, Missouri, Texas, Virginia
2022-03-10
Active, closed
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
NCT05156866Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
TORL Biotherapeutics, LLC
Phase 1
163
California, Indiana, Missouri, Texas
2022-02-02
Active, closed
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
NCT05159440Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
TORL Biotherapeutics, LLC
Phase 1
70
California, Indiana, Missouri
2022-01-20
Active, closed
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
DrugsEvorpacept·Ramucirumab·Herceptin·Taxol
ALX Oncology Inc.
Phase 2/3
127
California, Tennessee, Virginia, Washington
2022-01-15
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Nurix Therapeutics, Inc.
Phase 1
345
California, Colorado, Illinois, North Carolina, Oklahoma, Texas, Virginia, Washington
2021-09-29
Active, closed
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer
DrugSabestomig
AstraZeneca
Phase 1/2
136
Georgia, Indiana, New York, Tennessee
2021-09-28
Recruiting
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818Solid Tumor, Advanced Cancer, Metastatic Cancer, Gastric Cancer
DrugGivastomig
I-Mab Biopharma US Limited
Phase 1
330
California, Colorado, Indiana, Massachusetts, New Jersey, New York, North Carolina, Tennessee
2021-06-29
Active, closed
Idience Co., Ltd.
Phase 1/2
87
California, Louisiana, Massachusetts, New Jersey
2021-06-28
Active, closed
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT04868877Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
DrugsBispecific·Tagrisso·Osimertinib
Merus B.V.
Phase 1/2
194
California, Tennessee, Utah, Virginia
2021-04-28
Active, closed
CARsgen Therapeutics Co., Ltd.
Phase 1/2
110
California, Florida, Kansas, Michigan, Minnesota, New York, Ohio, Texas
2020-10-23
Active, closed
AstraZeneca
Phase 2
452
Maryland, Massachusetts, New York, Texas
2020-06-03
Active, closed
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
NCT04396821Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
DrugsTST001·MFOLFOX6·Albumin-Bound Paclitaxel·Opdivo
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
150
Arizona, Connecticut, Florida, Georgia, Kansas, Missouri, New York, North Carolina
2020-05-28
Active, closed
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
NCT03505320Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer, Pharmacokinetics of Oxaliplatin
DrugsZolbetuximab·Folinic acid·Fluorouracil·Leucovorin
Astellas Pharma Global Development, Inc.
Phase 2
143
California, Illinois, Massachusetts, New York
2018-06-29
Recruiting
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
DrugPetosemtamab
Merus B.V.
Phase 1/2
560
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Missouri, New York
2018-05-02
Recruiting
Apollomics Inc.
Phase 2
497
California, Florida, Massachusetts, North Carolina, Pennsylvania, Wisconsin
2017-09-27
Recruiting
Combination of TATE and PD-1 Inhibitor in Liver Cancer
NCT03259867Hepatocellular Carcinoma, Gastric Cancer
DrugOpdivo
Teclison Ltd.
Phase 2
54
California, Oklahoma, Wisconsin
2017-07-01
Recruiting
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244Colorectal Cancer, Pancreatic Cancer, Esophageal Cancer, Gastric Cancer
Lumicell, Inc.
Phase 1/2
66
Massachusetts
2016-08-04
Rows per page Showing 1–48 of 48
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/gastric-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 15 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 48 of those studies listing the condition Gastric Cancer.

How many Gastric Cancer trials are recruiting in the US?

28 of the 48 studies on this page are recruiting new participants as of the 15 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 19 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Gastric Cancer), 48 studies
PhaseStudiesRecruitingShare
Phase 1/217935.4%
Phase 114629.2%
Phase 211922.9%
Phase 3438.3%
Not applicable112.1%
Phase 2/3102.1%

Most active sponsors

Lead sponsors with the most studies (Gastric Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca95
Daiichi Sankyo22
HiFiBiO Therapeutics20
I-Mab Biopharma US Limited22
Merus B.V.21
Sutro Biopharma, Inc.21
TORL Biotherapeutics, LLC20
ALX Oncology Inc.10
Apollomics Inc.11
ArriVent BioPharma, Inc.11

Top states

Top states (Gastric Cancer), by number of studies with a site there
StateStudies
California36
Florida20
New York20
Texas19
Massachusetts14
Michigan11
Tennessee10
Virginia10
Missouri9
Colorado8
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.